General form of registration statement for all companies including face-amount certificate companies

Note 1 - Corporate Information 1 (Details Textual)

v3.24.4
Note 1 - Corporate Information 1 (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Mar. 27, 2024
Jul. 18, 2023
May 31, 2013
Net Income (Loss) Attributable to Parent $ (13,500) $ (6,775) $ (2,832) $ (13,483) $ (1,848) $ 18,691 $ (27,552)      
Retained Earnings (Accumulated Deficit)   (89,784)   (89,784)   (76,301) (94,992)      
Pieris Pharmaceuticals, Inc. [Member]                    
Reduction in Workforce, Percentage                 70.00%  
Reduction in Workforce, Cost           7,500        
Cash, Cash Equivalents, and Short-Term Investments   19,400   19,400   26,400        
Net Income (Loss) Attributable to Parent   (2,887) $ (10,752) (11,369) $ (19,959) (24,543) (33,277)      
Retained Earnings (Accumulated Deficit)   $ (326,333)   $ (326,333)   $ (314,964) $ (290,421)      
Pieris Pharmaceuticals, Inc. [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Phase 2 Trials [Member]                    
Contracts Receivable, Claims and Uncertain Amounts               $ 15,000    
Pieris Pharmaceuticals, Inc. [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Pivotal Clinical Trials [Member]                    
Contracts Receivable, Claims and Uncertain Amounts               40,000    
Pieris Pharmaceuticals, Inc. [Member] | Subsequent Event [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Phase 2 Trials [Member]                    
Contracts Receivable, Claims and Uncertain Amounts               20,000    
Pieris Pharmaceuticals, Inc. [Member] | Subsequent Event [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Pivotal Clinical Trials [Member]                    
Contracts Receivable, Claims and Uncertain Amounts               $ 55,000    
Pieris Pharmaceuticals GmbH [Member] | Pieris Pharmaceuticals, Inc. [Member]                    
Business Acquisition, Percentage of Voting Interests Acquired                   100.00%